Advanced Search
Lyell Immunopharma

Lyell Immunopharma

A biotechnology company developing cellular immunotherapies for treating cancer.

Lyell Immunopharma is a biotechnology company developing targeted cellular immunotherapies for treating any type of cancer that is headquartered in San Francisco, California and was founded in 2018 by Rick Klausner. The companies cellular immunotherapy products focus on using chimeric antigen receptor T (CAR-T) cells to treat solid tumors (which make up the majority of cancers). As of June 2019 the company has not publicly disclosed its official product pipeline despite receiving series A and series B funding from private investors.

Series A

On November 13, 2018 Lyell Immunopharma completed their series A funding round with an undisclosed amount of funding from undisclosed investors. The company is planning on using their series A funding for product development.

Series B

On February 8, 2019 Lyell Immunopharma completed their series B funding round with $179 million in funding from 8VC, Altitude Life Science Ventures, ARCH Venture Partners, Forsite Capital Management, and BMGI.


February 8, 2019
Lyell Immunopharma raises a $179,000,000 series B round.

Funding rounds


Further reading

Documentaries, videos and podcasts



Kate Goodwin
June 17, 2021
Biotech companies are dominating Nasdaq's IPO scheduled this week. Here's who is making their big public debut.
Ben Adams
May 26, 2021
Preclinical biotech Lyell Immunopharma is looking to go public after a whirlwind year of big deals and big bucks raises as it looks to use cell therapy to beat solid tumors.
Melanie Senior
April 1, 2021
Nature Biotechnology
Private biotech firms are awash with funding, raising record-breaking sums in 2020. Melanie Senior reports.
Crunchbase News
March 31, 2021
Crunchbase News
Crunchbase News' top picks of the news to stay current in the VC and startup world.


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.